Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose (MTD) of single agent carfilzomib in patients with
relapsed and refractory peripheral T-cell lymphoma (PTCL) including angioimmunoblastic T-cell
lymphoma (AITL), anaplastic large cell lymphoma (ALCL) anaplastic lymphoma receptor tyrosine
kinase (ALK)+/ALK-, adult T-cell leukemia/lymphoma (ATLL), natural killer (NK)-cell lymphoma
(NKL), transformed mycosis fungoides (MF) to large cell, and PTCL-unspecified (PTCL-U).

II. To assess the safety and preliminary efficacy of single agent carfilzomib in patients
with relapsed and refractory peripheral T-cell lymphoma (PTCL) including angioimmunoblastic
T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) ALK+/ALK-, adult T-cell
leukemia/lymphoma (ATLL), NK-cell lymphoma (NKL), transformed mycosis fungoides (MF) to large
cell, and PTCL-unspecified (PTCL-U).

III. To evaluate nuclear transcription factor kappa-B (NF-kappa B) activation in PTCL tumor
tissue and correlate that with response to carfilzomib, a novel proteosome inhibitor, which
targets NF-kappa B.

OUTLINE: This is a dose escalation study.

Patients receive carfilzomib intravenously (IV) over 30 minutes on days 1, 2, 8, 9, 15, and
16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression
or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for year 1, then
every 4 months for year 2, then every 6 months for years 3 and 4, and then yearly thereafter.

Inclusion Criteria:

- Relapsed and refractory PTCL, including angioimmunoblastic T-cell lymphoma (AITL),
anaplastic large cell lymphoma (ALCL) ALK+/ALK-, adult T-cell leukemia/lymphoma
(ATLL), NK-cell lymphoma (NKL), transformed MF to large cell, and PTCL-unspecified
(PTCL-U) patients who have failed standard therapy/transplant for their histological
confirmed disease or who are not transplant eligible are eligible to participate in
this trial

- Karnofsky performance status >= 70

- ANC >= 700 cells/mm^3, unless due to lymphoma involvement of the bone marrow or spleen

- Platelet count >= 50 mm^3, unless due to lymphoma involvement of the bone marrow or
spleen

- Hemoglobin >= 8 g/dL, unless due to lymphoma involvement of the bone marrow

- Liver functions (AST, ALT, bilirubin) =< 3 x upper limits of normal (ULN) unless due
to lymphoma or due to Gilberts disease

- Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 40 mL/min
(Cockcroft-Gault)

- LVEF >= 40% 2-D transthoracic ECHO is the preferred method of evaluation; MUGA scan is
acceptable if ECHO is not available

- Able to adhere to the study visit schedule and other protocol requirements

- Patients must be willing to give written informed consent, and sign an institutionally
approved consent form before performance of any study-related procedure not part of
normal medical care, with the understanding that consent may be withdrawn by the
subject at any time without prejudice to future medical care

- Non-pregnant and non-nursing; men and women of reproductive potential may not
participate unless they have agreed to use an effective contraceptive method while on
the study

- No serious disease or condition that, in the opinion of the investigator, would
compromise the patient's ability to participate in the study

- Patients with a history of coronary artery disease, congestive heart failure,
hypertension, diabetes, or hyperlipidemia must have a MUGA or echocardiography,
performed within 2 months of study entry

Exclusion Criteria:

- Pregnant or breast feeding females

- Active serious infection requiring treatment within 14 days prior to the start of
carfilzomib

- Active hepatitis or uncontrolled HIV

- Unstable angina or myocardial infarction within 6 months prior to enrollment, New York
Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, history
of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick
sinus syndrome, or EKG evidence of acute ischemia or Grade 3 conduction system
abnormalities unless subject has a pacemaker

- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to the start
of carfilzomib

- Patients in whom the schedule of oral and IV fluid hydration is contraindicated, e.g.,
due to pre-existing pulmonary, cardiac, or renal impairment

- Prior malignancies within the past 2 years with exception of adequately treated basal
cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix or
breast; prostate cancer of Gleason grade 6 or less with stable prostate specific
antigen (PSA) levels

- Significant peripheral neuropathy (grades 3-4, or grade 2 with pain) within 14 days
prior to the start of carfilzomib

- Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize
carfilzomib)

- Concurrent use of other anti-cancer agents, investigative agents, or treatments

- Contraindication to any of the required concomitant drugs or supportive treatments,
including hypersensitivity to all anticoagulation and antiplatelet options, antiviral
drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

- Any other clinically significant medical disease or condition laboratory abnormality
or psychiatric illness that, in the Investigator's opinion, may interfere with
protocol adherence or a subject's ability to give informed consent